107,061 Charles River Laboratories International, Inc. $CRL Shares Acquired by State of Alaska Department of Revenue

State of Alaska Department of Revenue increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2,268.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,781 shares of the medical research company’s stock after acquiring an additional 107,061 shares during the quarter. State of Alaska Department of Revenue’s holdings in Charles River Laboratories International were worth $32,977,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Continuum Advisory LLC acquired a new stake in Charles River Laboratories International during the 2nd quarter valued at $30,000. SHP Wealth Management acquired a new stake in shares of Charles River Laboratories International in the fourth quarter worth $85,000. Hilltop National Bank boosted its position in shares of Charles River Laboratories International by 28.7% in the second quarter. Hilltop National Bank now owns 569 shares of the medical research company’s stock worth $129,000 after buying an additional 127 shares during the period. Trust Asset Management LLC purchased a new position in shares of Charles River Laboratories International during the second quarter valued at $129,000. Finally, ABS Direct Equity Fund LLC acquired a new position in Charles River Laboratories International during the first quarter valued at $172,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on CRL. UBS Group initiated coverage on Charles River Laboratories International in a research report on Wednesday, September 30th. They set a “buy” rating and a $357.00 price objective for the company. Morgan Stanley raised their price target on shares of Charles River Laboratories International from $300.00 to $340.00 and gave the stock an “overweight” rating in a report on Monday. TD Cowen boosted their price objective on shares of Charles River Laboratories International from $300.00 to $325.00 and gave the company a “buy” rating in a research report on Friday, September 25th. BNP Paribas Exane set a $250.00 price objective on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Finally, Evercore set a $330.00 price objective on shares of Charles River Laboratories International in a research note on Friday, September 25th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $302.33.

Insider Activity at Charles River Laboratories International

In related news, EVP Shannon M. Parisotto sold 5,046 shares of Charles River Laboratories International stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $263.00, for a total value of $1,327,098.00. Following the completion of the sale, the executive vice president owned 4,807 shares of the company’s stock, valued at approximately $1,264,241. The trade was a 51.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Birgit Girshick sold 6,500 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the completion of the sale, the chief executive officer owned 36,013 shares of the company’s stock, valued at $10,080,038.70. This represents a 15.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 91,971 shares of company stock worth $26,033,968 over the last quarter. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Stock Up 1.8%

Shares of Charles River Laboratories International stock traded up $5.40 during trading on Thursday, hitting $307.40. 389,636 shares of the stock traded hands, compared to its average volume of 929,006. The stock has a market cap of $14.68 billion, a P/E ratio of -63.41, a PEG ratio of 2.79 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. Charles River Laboratories International, Inc. has a twelve month low of $146.20 and a twelve month high of $333.30. The company has a fifty day moving average price of $288.02 and a two-hundred day moving average price of $226.13.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same quarter in the prior year, the company posted $3.12 earnings per share. The firm’s revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities research analysts predict that Charles River Laboratories International, Inc. will post 11.38 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.